All In Biotech

Drug Trial Radar · NCT04716712

Infant Mortality Reduction by the Mass Administration of Azithromycin

Mortalite Infantile Reduite Par l'Administration de Masse de l'Azitromycine

Last checked: Nov 19, 2026Latest source record: Mar 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 694,400 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

694,400

Planned (sponsor's estimate)

Start

Oct 4, 2021

Primary completion

Jan 30, 2025

Study completion Jan 30, 2026

Sponsor

Lead sponsor
University of California, San FranciscoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Helen Keller International; Centre de Recherche en Sante de Nouna, Burkina Faso; Bill and Melinda Gates Foundation
First posted
Jan 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 1 month, up to 11 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This trial will investigate the supplementation of azithromycin distribution to the "Child Health Days" platform in Burkina Faso for child mortality reduction. This distribution will pair door-to-door administration of vitamin A and azithromycin or placebo with acute malnutrition screening among children 1-11 months old.

Conditions

  • Child Mortality

Interventions

  • AzithromycinDrug

    Azithromycin is a macrolide-type antibiotic that is used to treat various types of infections. Previous studies in Niger have demonstrated a nearly 18% reduction in all-cause child mortality following biannual mass administration to children 1-59 months.

  • PlaceboDrug

    Matching identical placebo in packaging, appearance, and taste.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All-cause mortalityTime frame: 24 months following baseline

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California, San Francisco

    San Francisco, California

  • Centre de Recherche en Sante de Nouna

    Nouna, Burkina Faso

  • Helen Keller International

    Ouagadougou, Burkina Faso

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.